Aliskiren Market

The Aliskiren market is witnessing a CAGR of 2.4% during the forecast period of 2025-2035. Aliskiren is a direct renin inhibitor (DRI) used to treat excessive blood pressure. It acts by inhibiting the action of renin, an enzyme that activates the renin-angiotensin-aldosterone system (RAAS), lowering blood pressure and avoiding cardiovascular problems. Aliskiren, a first-in-class renin inhibitor, provides an alternative to angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) in the treatment of hypertension and related cardiovascular problems.

The pharmaceutical industry is heavily involved in the production and commercialization of Aliskiren, with major medication manufacturers developing both branded and generic forms. Despite its potential benefits for blood pressure control, Aliskiren’s market presence has been hampered by safety concerns, regulatory warnings, and competition from existing antihypertensive medications. Some studies have connected Aliskiren to an increased risk of kidney impairment, hyperkalemia, and cardiovascular events, prompting limits on its usage, particularly when combined with ACE inhibitors or ARBs in patients with diabetes or kidney disease.

The healthcare and hospital sectors continue to be the principal end consumers, with cardiologists and general practitioners prescribing Aliskiren to patients who seek alternative or adjunct hypertension treatments. Additionally, the biotechnology and pharmaceutical research sectors continue to investigate new formulations and combination medications to improve efficacy and reduce negative effects.